Boston –Researchers from Brigham and Women's Hospital (BWH) have developed a risk score calculation that can help predict which patients with rhabdomyolysis (a condition that occurs due to muscle damage) may be at risk for the severe complication of kidney failure or death. This research will publish online September 2, 2013 in JAMA Internal Medicine.
Rhabdomyolysis occurs when muscles are crushed and rupture, leaking toxic compounds into the circulation and can be caused by any condition that damages skeletal muscle and causes injury. Risk factors include crush injuries, alcoholism, heat stroke or severe exertion including strenuous exercise and as a rare side effect of taking cholesterol lowering medications called statins. One of the compounds called myoglobin can get caught in the kidneys and cause kidney failure and even death in severe cases.
"Currently doctors cannot easily predict which patients are most likely to have severe kidney failure or die from rhabdomyolysis," explained Gearoid McMahon, MB, BCh, a clinical fellow in BWH's Department of Medicine and lead author on this study. "Using routinely available clinical variables, we have developed a new risk prediction score that doctors can use to help predict a patient's expected outcome and plan for treatment accordingly."
The researchers conducted a retrospective cohort study of 2,371 patients admitted between 2000 and 2011 and analyzed variables that are thought to be associated with poor outcomes in this patient population, such as age, gender, and CPK levels. Using data from this analysis, researchers created a risk prediction score based on the variables that were most significantly associated with poor outcomes. The final variables that were included in the created model were age, gender, levels of initial phosphate, calcium, creatinine and CO2, CPK, and cause of rhabdomyolysis.
"This model may be particularly useful to evaluate and triage patients in the Emergency Department (ED)," said Sushrut Waikar, MD, MPH, director of Renal and Ambulatory Services at BWH and senior author of the study. "By current practice standards, patients with rhabdomyolysis are treated similarly regardless of the underlying cause and overall risk profile. Knowledge of the predicted risk of adverse outcomes may lead clinicians to choose different treatment options such as intravenous fluid administration in the ED followed by discharge with plans for repeat outpatient labs, rather than inpatient hospitalization for observation."
The researchers note that the next step will be to validate this risk score in other populations and to test its ability to guide treatment decisions. An online version of the Brigham rhabdomyolysis risk score is available at: http://www.brighamandwomens.org/research/rhabdo/default.aspx.
This research is consistent with the recent trend in medicine toward patient-centered outcomes research (PCOR), which focuses on identifying the risk of each patient and tailoring the treatment to improve their individual outcomes. BWH recently established the Patient-centered Comparative Effectiveness Research Center (PCERC) for researchers, like McMahon, that are dedicated to improving the health outcomes of BWH patients.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs more than 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.